MA40481A - Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante - Google Patents

Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante

Info

Publication number
MA40481A
MA40481A MA040481A MA40481A MA40481A MA 40481 A MA40481 A MA 40481A MA 040481 A MA040481 A MA 040481A MA 40481 A MA40481 A MA 40481A MA 40481 A MA40481 A MA 40481A
Authority
MA
Morocco
Prior art keywords
pyridin
isocitrate dehydrogenase
dehydrogenase inhibitors
mutant isocitrate
quinolinone derivatives
Prior art date
Application number
MA040481A
Other languages
English (en)
Inventor
Susan Ashwell
Ann-Marie Campbell
Justin Andrew Caravella
R Bruce Diebold
Anna Ericsson
Gary Gustafson
Jr David R Lancia
Jian Lin
Wei Lu
Zhongguo Wang
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of MA40481A publication Critical patent/MA40481A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne des inhibiteurs de protéines d'isocitrate déshydrogénase mutantes (mt-idh) ayant une activité néomorphe, utiles pour traiter les troubles liés à la prolifération cellulaire et les cancers, de formule : (i) où a, u, w1, w2, w3, r1-r6, et r9 sont tels que décrits dans la présente.
MA040481A 2014-09-19 2015-09-18 Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante MA40481A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462053006P 2014-09-19 2014-09-19
US201562128089P 2015-03-04 2015-03-04
US201562150812P 2015-04-21 2015-04-21

Publications (1)

Publication Number Publication Date
MA40481A true MA40481A (fr) 2017-07-26

Family

ID=54291606

Family Applications (2)

Application Number Title Priority Date Filing Date
MA053352A MA53352A (fr) 2014-09-19 2015-09-18 Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
MA040481A MA40481A (fr) 2014-09-19 2015-09-18 Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA053352A MA53352A (fr) 2014-09-19 2015-09-18 Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase

Country Status (37)

Country Link
US (8) US9834539B2 (fr)
EP (4) EP4257131A3 (fr)
JP (1) JP6648115B2 (fr)
KR (1) KR102209667B1 (fr)
CN (3) CN117695280A (fr)
AU (3) AU2015317329B2 (fr)
BR (1) BR112017005238B1 (fr)
CA (1) CA2961817C (fr)
CL (1) CL2017000658A1 (fr)
CO (1) CO2017003241A2 (fr)
CY (2) CY1121149T1 (fr)
DK (2) DK3447050T3 (fr)
EA (1) EA034336B1 (fr)
EC (1) ECSP17022933A (fr)
ES (3) ES2790640T3 (fr)
FI (1) FI3733662T3 (fr)
HR (1) HRP20200666T1 (fr)
HU (2) HUE041460T2 (fr)
IL (3) IL292608B2 (fr)
LT (2) LT3194376T (fr)
MA (2) MA53352A (fr)
ME (1) ME03776B (fr)
MX (2) MX2017003404A (fr)
MY (2) MY176250A (fr)
NZ (1) NZ730373A (fr)
PE (1) PE20171056A1 (fr)
PH (1) PH12017500517B1 (fr)
PL (3) PL3194376T3 (fr)
PT (3) PT3733662T (fr)
RS (2) RS58184B1 (fr)
SA (1) SA517381129B1 (fr)
SG (1) SG11201702194SA (fr)
SI (2) SI3447050T1 (fr)
SM (2) SMT202000212T1 (fr)
TW (1) TWI686390B (fr)
WO (1) WO2016044789A1 (fr)
ZA (3) ZA201702127B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108524505A (zh) 2009-03-13 2018-09-14 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
EP3561077B1 (fr) * 2009-10-21 2022-12-21 Les Laboratoires Servier Procédés pour des troubles liés à la prolifération cellulaire
MX393637B (es) 2014-02-06 2025-03-11 Heptares Therapeutics Ltd Compuestos aza biciclicos como agonistas del receptor muscarinico m1.
WO2016044782A1 (fr) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Dérivés de phénylquinoléinone en tant qu'inhibiteurs d'isocitrate déshydrogénase mutante
JP6751081B2 (ja) 2014-09-19 2020-09-02 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体
SI3447050T1 (sl) * 2014-09-19 2020-08-31 Forma Therapeutics, Inc. Derivati piridin-2(1H)-on kinolinona kot inhibitorji mutirane izocitratne dehidrogenaze
PE20170697A1 (es) 2014-09-19 2017-06-24 Bayer Pharma AG Indazoles sustituidos con benzilo como inhibidores de bub1
CA2961793C (fr) * 2014-09-19 2021-03-16 Forma Therapeutics, Inc. Compositions de quinoleinone pyrimidines en tant qu'inhibiteurs d'isocitrate deshydrogenase mutante
CN107428690B (zh) * 2014-12-22 2021-04-13 美国政府健康及人类服务部 可用于治疗癌症的突变idh1抑制剂
US10294206B2 (en) 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
PL3619196T3 (pl) 2017-05-04 2022-08-29 Bayer Cropscience Aktiengesellschaft Pochodne 2-{[2-(fenyloksymetylo)pirydyn-5-yl]oksy}-etanoaminy i związki pokrewne jako środki do zwalczania szkodników np. do ochrony upraw
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US10532047B2 (en) 2018-05-16 2020-01-14 Forma Therapeutics, Inc. Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
MD3720442T2 (ro) 2018-05-16 2023-09-30 Forma Therapeutics Inc Inhibare de IDH-1 mutant
US11576906B2 (en) 2018-05-16 2023-02-14 Forma Therapeutics, Inc. Inhibiting mutant IDH-1
WO2020232381A1 (fr) 2019-05-16 2020-11-19 Forma Therapeutics, Inc. Inhibition de l'isocitrate déshydrogénase 1 mutante (midh-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
TW202104207A (zh) * 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
US11566013B1 (en) * 2019-11-20 2023-01-31 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
CN112321571B (zh) * 2020-10-27 2022-06-03 浙江工业大学 2-呋喃-喹啉-4-甲酰胺类化合物及其应用
CN112341389B (zh) * 2020-10-27 2022-07-29 浙江工业大学 一种含氮芳杂环取代的喹啉甲酰胺类衍生物及其应用
CN115850240B (zh) * 2022-12-28 2023-09-19 北京康立生医药技术开发有限公司 一种治疗急性髓系白血病药物奥卢他西尼的合成方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US20030105124A1 (en) 2000-04-27 2003-06-05 Susan Beth Sobolov-Jaynes Substituted benzolactam compounds
MXPA04012440A (es) 2002-06-12 2005-04-28 Abbott Lab Antagonistas de receptor de hormona concentradora de melanina.
WO2004043936A1 (fr) 2002-11-14 2004-05-27 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de plk (kinases du type polo)
RU2284325C2 (ru) * 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
EP1749827A4 (fr) 2004-03-30 2010-04-21 Kyowa Hakko Kirin Co Ltd Agent anti tumoral
WO2006054912A1 (fr) 2004-11-18 2006-05-26 Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
US20100056516A1 (en) * 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
JP2010043004A (ja) 2006-12-06 2010-02-25 Dainippon Sumitomo Pharma Co Ltd 新規２環性複素環化合物
BRPI0810921A2 (pt) 2007-04-30 2014-10-29 Prometic Biosciences Inc Derivados de triazina, composições contendo tais derivados e métodos de tratamento de câncer e doenças autoimunes usando tais compostos
CA2764785C (fr) 2009-06-08 2015-10-27 California Capital Equity, Llc Derives de triazine et leurs applications therapeutiques
JP5967827B2 (ja) * 2009-12-09 2016-08-10 アジオス ファーマシューティカルズ， インコーポレイテッド Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物
US9073941B2 (en) 2010-06-28 2015-07-07 Academia Sinica Compounds and methods for treating tuberculosis infection
CN102558049B (zh) * 2010-12-17 2015-02-04 中国科学院上海药物研究所 一类双香豆素类化合物及其制备方法和用途
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103814020B (zh) * 2011-06-17 2017-07-14 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
CN104271132B (zh) 2011-12-21 2018-01-12 科罗拉多大学董事会法人团体 靶向Ral GTP酶的抗癌化合物及使用其的方法
ES2675760T3 (es) 2012-01-06 2018-07-12 Agios Pharmaceuticals, Inc. Compuestos terapéuticamente activos y métodos de uso de los mismos
JP2016514124A (ja) 2013-03-14 2016-05-19 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
WO2015003146A1 (fr) 2013-07-03 2015-01-08 Georgetown University Dérivés acide boronique de resvératrol pour l'activation des enzymes désacétylases
WO2015121210A1 (fr) 2014-02-11 2015-08-20 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines en tant qu'inhibiteurs midh1
CA2961793C (fr) 2014-09-19 2021-03-16 Forma Therapeutics, Inc. Compositions de quinoleinone pyrimidines en tant qu'inhibiteurs d'isocitrate deshydrogenase mutante
WO2016044782A1 (fr) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Dérivés de phénylquinoléinone en tant qu'inhibiteurs d'isocitrate déshydrogénase mutante
SI3447050T1 (sl) 2014-09-19 2020-08-31 Forma Therapeutics, Inc. Derivati piridin-2(1H)-on kinolinona kot inhibitorji mutirane izocitratne dehidrogenaze
JP6751081B2 (ja) 2014-09-19 2020-09-02 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体
CN107428690B (zh) 2014-12-22 2021-04-13 美国政府健康及人类服务部 可用于治疗癌症的突变idh1抑制剂
GB2533925A (en) 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
US10294206B2 (en) 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
WO2017019429A1 (fr) 2015-07-27 2017-02-02 Eli Lilly And Company Coposés de 7-phényléthylamino -4 h-pyrimido [4,5-d] [1,3] oxazin-2-one et leur utilisation en tant qu'inhibiteurs de idh1 mutante
CA3015753A1 (fr) 2016-02-26 2017-08-31 Celgene Corporation Inhibiteurs d'idh2 pour le traitement de tumeurs solides et malignes hematologiques
CN109311863B (zh) 2016-06-06 2021-10-29 伊莱利利公司 突变型idh1抑制剂
CN109641887B (zh) 2016-06-22 2022-09-20 美国政府健康及人类服务部 可用作用于治疗癌症的突变idh1抑制剂的噻唑衍生物
ES2835281T3 (es) 2016-12-16 2021-06-22 Lilly Co Eli Compuestos de 7-feniletilamino-4H-pirimido[4,5-d][1,3]oxazin-2-ona como inhibidores de IDH1 e IDH2 mutantes

Also Published As

Publication number Publication date
ZA201902446B (en) 2023-12-20
AU2021215141B2 (en) 2023-10-19
US10889567B2 (en) 2021-01-12
US10550098B2 (en) 2020-02-04
EA201790657A1 (ru) 2017-08-31
PH12017500517B1 (en) 2022-08-03
IL282363A (en) 2021-06-30
EA201790657A8 (ru) 2018-02-28
CN117695280A (zh) 2024-03-15
MX2017003404A (es) 2017-07-28
TWI686390B (zh) 2020-03-01
CL2017000658A1 (es) 2017-12-22
HUE062424T2 (hu) 2023-11-28
CY1122865T1 (el) 2021-05-05
EP4257131A3 (fr) 2024-01-10
SI3194376T1 (sl) 2019-03-29
US20240150319A1 (en) 2024-05-09
IL282363B (en) 2022-06-01
IL292608A (en) 2022-07-01
EP3447050B1 (fr) 2020-02-19
EP3733662A1 (fr) 2020-11-04
CA2961817C (fr) 2024-03-12
DK3447050T3 (da) 2020-03-09
EP3194376A1 (fr) 2017-07-26
IL292608B1 (en) 2024-06-01
BR112017005238B1 (pt) 2023-01-17
HUE041460T2 (hu) 2019-05-28
US20210078973A1 (en) 2021-03-18
KR20170063742A (ko) 2017-06-08
US20180312487A1 (en) 2018-11-01
EP4257131A2 (fr) 2023-10-11
RS60140B1 (sr) 2020-05-29
PL3447050T3 (pl) 2020-07-27
AU2021215141A1 (en) 2021-09-02
AU2015317329B2 (en) 2019-10-31
US12275715B2 (en) 2025-04-15
MY176250A (en) 2020-07-24
SG11201702194SA (en) 2017-04-27
SI3447050T1 (sl) 2020-08-31
CN107001328B (zh) 2020-06-05
PL3733662T3 (pl) 2024-01-22
ES2790640T3 (es) 2020-10-28
CA2961817A1 (fr) 2016-03-24
TW201617335A (zh) 2016-05-16
LT3194376T (lt) 2019-02-25
NZ758641A (en) 2023-12-22
PH12017500517A1 (en) 2017-08-07
US20160083366A1 (en) 2016-03-24
ES2953347T3 (es) 2023-11-10
LT3447050T (lt) 2020-05-11
WO2016044789A1 (fr) 2016-03-24
MY197533A (en) 2023-06-21
CO2017003241A2 (es) 2017-09-20
CN111909130B (zh) 2023-10-31
AU2019283765A1 (en) 2020-01-16
EP3447050A1 (fr) 2019-02-27
ECSP17022933A (es) 2017-08-31
SMT201900018T1 (it) 2019-02-28
FI3733662T3 (fi) 2023-08-09
EA034336B1 (ru) 2020-01-29
MX385512B (es) 2025-03-18
CN111909130A (zh) 2020-11-10
IL251163B (en) 2021-05-31
CY1121149T1 (el) 2020-05-29
US20170174658A1 (en) 2017-06-22
ZA202304409B (en) 2024-08-28
HRP20200666T1 (hr) 2020-07-24
ME03776B (fr) 2021-04-20
US11498913B2 (en) 2022-11-15
JP2017528487A (ja) 2017-09-28
DK3194376T3 (en) 2019-01-21
EP3194376B1 (fr) 2018-10-24
ZA201702127B (en) 2019-06-26
US10414752B2 (en) 2019-09-17
SA517381129B1 (ar) 2021-04-26
PT3733662T (pt) 2023-08-18
JP6648115B2 (ja) 2020-02-14
US20190263778A1 (en) 2019-08-29
IL292608B2 (en) 2024-10-01
MX2019013203A (es) 2020-01-20
US20230125739A1 (en) 2023-04-27
US20200223822A1 (en) 2020-07-16
EP3733662B1 (fr) 2023-06-07
SMT202000212T1 (it) 2020-05-08
PL3194376T3 (pl) 2019-05-31
IL251163A0 (en) 2017-04-30
BR112017005238A2 (pt) 2017-12-19
AU2015317329A1 (en) 2017-04-27
PE20171056A1 (es) 2017-07-21
AU2019283765B2 (en) 2021-05-13
NZ730373A (en) 2019-11-29
MA53352A (fr) 2021-09-15
PT3194376T (pt) 2019-02-04
KR102209667B1 (ko) 2021-01-29
ES2704897T3 (es) 2019-03-20
CN107001328A (zh) 2017-08-01
PT3447050T (pt) 2020-09-17
US9834539B2 (en) 2017-12-05
RS58184B1 (sr) 2019-03-29

Similar Documents

Publication Publication Date Title
MA40481A (fr) Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MX2018015625A (es) Compuestos y composiciones para inhibir la actividad de shp2.
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA202092636A1 (ru) Способ синтеза 2-гидрокси-6-((2-(1-изопропил-1h-пиразол-5-ил)пиридин-3-ил)метокси)бензальдегида
EA200601364A1 (ru) Производные хинолина и их применение в качестве ингибиторов микобактерий
EA201792047A1 (ru) Новые соединения
EA201690199A1 (ru) Лекарственное средство для лечения неалкогольной жировой болезни печени
MX391812B (es) Agonista fxr derivado de esteroides.
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
MA39172B1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
MX373102B (es) Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
EP3778605A3 (fr) Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MA35643B1 (fr) Inhibiteur de cetp d'oxazolidinone bicyclique condensée
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201690752A1 (ru) Ингибиторы g12c kras
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EA201391288A1 (ru) Производные пиразолоспирокетонов для применения в качестве ингибиторов ацетил-коа-карбоксилаз
MA40993A (fr) Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation